Spotlight On... Pending Allergan merger stirs layoff fears among Pfizer scientists; Biogen joins a $20M ALS fundraise drive; Biden picks key adviser to lead 'moonshot' program; and more...

Pfizer's ($PFE) planned $160 billion merger with Allergan ($AGN) has some researchers worried the company will embrace its counterpart's austere approach to R&D and mount major layoffs. As the Financial Times reports, Pfizer top scientist Mikael Dolsten is working to assuage those fears in his department, saying the combined company will find a "sweet spot" in R&D that will preserve Pfizer's long-held commitment to research. Allergan executives, long averse to costly R&D, have "opened their eyes" to the benefits of spending big on early-stage research, Dolsten told FT. But some Pfizer scientists, mindful of pharma M&A history, remain concerned that the company will substantially cut back its R&D budget once the merger closes this summer, according to FTStory

@FierceBiotech: Oxford team fingers an inflammatory protein as a trigger for cancer. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: AbbVie taps Synlogic to take a microbiomic approach to IBD. News | Follow @JohnCFierce

@DamianFierce: oh to be a fly on the wall as WSJ editors discussed how best to word this paragraph. More/Article (sub. req.) | Follow @DamianFierce

> Biogen ($BIIB) has donated $5 million to the Target ALS Foundation to help launch a program seeking $20 million from other industry contributors to support research into treatments for amyotrophic lateral sclerosis, or Lou Gehrig's disease. More

> Vice President Joe Biden has appointed policy adviser Don Graves to head up his "moonshot" initiative, designed to accelerate the development of new cancer therapies. News

> Roche's ($RHHBY) lung cancer drug Alecensa, approved in the U.S. last year, succeeded in a Japanese study comparing it with Pfizer's ($PFE) Xalkori, leading investigators to stop the study early. Item

Medical Device News

@FierceMedDev: ICYMI yesterday: BTG, Philips roll out first cancer embolic bead visible via real-time imaging. Article | Follow @FierceMedDev

@EmilyWFierce: Hikma slashes $535M from offer price for Boehringer's U.S. generics biz. FiercePharma story | Follow @EmilyWFierce

> Smith & Nephew to sell OrthAlign precision alignment tech alongside its artificial knees. Story

> As Zika fears spread, Cerus nabs American Red Cross partnership for blood pathogen reduction. Article

Pharma News

@FiercePharma: Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics.' Article | Follow @FiercePharma

@CarlyHFierce: ICYMI: Actelion exceeds profit estimates as Opsumit, Uptravi make up for aged Tracleer. Report | Follow @CarlyHFierce

> Novartis defies naysayers with newfangled pay-for-performance deals on Entresto. Story

> Hikma slashes $535M from offer price for Boehringer's U.S. generics biz. Article

Pharma Marketing News

> Novartis bolsters its home-turf advantage in psoriasis with Cosentyx DTC push. Story

> Big Pharma's new PCSK9, heart failure meds stuck in the slow lane. What gives? More

> Pfizer and Valeant jump in annual brand analysis, but most other pharmas drop. Report

> FDA pushes CTI to pull app for myelofibrosis med after trial deaths. Item

> PhRMA hopes to polish pharma's tarnished rep with patient-focused ad campaign. Article

Biotech Research News

> Oxford team fingers an inflammatory protein as a trigger for cancer. Report

> Study: LDL, omega-3 nano-strategy eliminates liver cancer cells in rats. More

> Sequencing deer tick genome may help stop Lyme disease one day. Item

> CRUK scientists ID a key player behind the spread of breast cancer cells. Story

> NIH researchers find genomic signature common in 5 types of cancer. Article

Vaccines News

> As corporate restructuring looms, Sanofi's vaccines deliver in 2015. More

> Zika update: Vaccine race swells, PaxVax CEO on how to stop 'chasing epidemics.' Report

> GlaxoSmithKline signs two new vaccine R&D partnerships. Story

> Bavarian Nordic launches MRSA vaccine effort with partner Evaxion. Item

> GSK's vax revenues jump in 2015 while profit, margin slip. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.